
Santiago Escriva-de-Romani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1349083/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	HER2-positive breast cancer: Current and new therapeutic strategies. Breast, 2018, 39, 80-88.	0.9	89
2	SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx) Journal of Clinical Oncology, 2019, 37, 1000-1000.	0.8	71
3	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. Clinical Cancer Research, 2020, 26, 5820-5829.	3.2	68
4	p95HER2–T cell bispecific antibody for breast cancer treatment. Science Translational Medicine, 2018, 10, .	5.8	59
5	The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1. Cancers, 2020, 12, 670.	1.7	31
6	Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. Cancers, 2020, 12, 3509.	1.7	7
7	Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer. Expert Review of Anticancer Therapy, 2020, 20, 731-741.	1.1	6
8	Paraneoplastic cerebellar degeneration diagnosed by anti-Yo determination in a young woman with early breast cancer. BMJ Case Reports, 2020, 13, e233863.	0.2	4
9	Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC) Journal of Clinical Oncology, 2019, 37, 1075-1075.	0.8	2
10	Abstract OT2-27-01: Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC). Cancer Research, 2022, 82, OT2-27-01-OT2-27-01.	0.4	1